Sun Xiayu, Yang Jun
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Dec;34(12):1149-1152. doi: 10.13201/j.issn.2096-7993.2020.12.023.
Sensorineural hearing loss(SNHL) is a difficult and hot issue in the field of otology. The effect of medications targeting the mechanism of SNHL are often unsatisfactory for hearing improvement. Hearing aids and cochlear implants are the mainstream treatment methods at present, but neither of them can reverse the pathological changes of affected inner ear. In recent years, mesenchymal stem cells transplantation has been confirmed by several animal studies and clinical trials to have great potential for clinical applications in restoring the structure of the inner ear and hearing improvement to some extent. In this review, we review the characteristics of umbilical cord blood derived mesenchymal stem cells(UCBMSCs), the approaches of transplantation, the efficacy and mechanism of UCBMSCs in the treatment of SNHL, and the safety of clinical application, covering the existing problems and future prospects of this rising treatment.
感音神经性听力损失(SNHL)是耳科学领域的一个难题和热点问题。针对SNHL发病机制的药物治疗在改善听力方面的效果往往不尽人意。助听器和人工耳蜗是目前的主流治疗方法,但它们都无法逆转受影响内耳的病理变化。近年来,多项动物研究和临床试验证实,间充质干细胞移植在一定程度上恢复内耳结构和改善听力方面具有巨大的临床应用潜力。在这篇综述中,我们回顾了脐带血来源的间充质干细胞(UCBMSCs)的特性、移植途径、UCBMSCs治疗SNHL的疗效和机制以及临床应用的安全性,涵盖了这种新兴治疗方法存在的问题和未来前景。